Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1248.65
₹7.90(0.63%)
At close: 4:00 PM EDT
₹1248.65
₹7.90(0.63%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹1,803.60
Previous CloseN/A
Volume79.36K
Average Volume (3M)12.81K
Market Cap
₹148.59B
Enterprise Value₹101.96K
Total Cash (Recent Filing)₹4.16B
Total Debt (Recent Filing)₹23.16M
Price to Earnings (P/E)54.1
Beta1.21
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)24.86
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33.34
Revenue Forecast (FY)₹13.06B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and a steadily increasing equity base materially reduce refinancing and solvency risk. For a capital‑intensive API manufacturer this durable conservatism preserves financial flexibility to fund capacity, absorb regulatory delays, and support long sales cycles over the next 2–6 months.
Consistent Cash GenerationOperating cash consistently outpacing reported earnings indicates high earnings quality and internal funding capacity. The 2026 free cash flow rebound supports reinvestment in fermentation capacity and working capital, enabling stable supply contracts and incremental product development over the medium term.
Healthy Profitability MarginsSustained gross and operating margins reflect the company’s fermentation expertise and complex API mix, which are structural competitive advantages. Robust margins provide cushion against cyclical demand and fund R&D or scale-up, supporting durable cash flow generation and returns over coming quarters.
Bears Say
Revenue Decline In 2026A material drop in annual revenue after multiple years of expansion signals demand headwinds or lost share in key API segments. Lower top-line volumes can undercut scale economics and prolong margin recovery, challenging capacity utilization and growth visibility for the next several quarters.
Margin Compression From Prior PeaksCompression from peak margins suggests normalization or emerging pricing/ cost pressure in core APIs. If sustained, this reduces internal funding for expansion or R&D and increases sensitivity to volume swings, making profit stability over a 2–6 month horizon less certain.
Free Cash Flow VolatilityIntermittent negative FCF and uneven reinvestment patterns indicate working‑capital or capex timing risks. Volatility hampers predictability of funds available for capacity builds, partnerships, or shareholder returns, raising execution risk for multi‑quarter strategic initiatives.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹1803.60 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹148.59B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 107 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Jul 31, 2026. The company reported ₹5.8 earnings per share for the quarter, missing the consensus estimate of ₹7.333 by -₹1.533.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Annually dividend of ₹7.55 which represents an annual dividend yield of 0.53%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹5.8 in its last earnings report, missing expectations of ₹7.333. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―
Anthem Biosciences Limited
―